Physician profile
Vikas Gupta
NPI 1710974167
$3,368.88
in general payments reported to CMS, 2019-2025
40 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $462 · 2021: $465 · 2022: $282 · 2023: $458 · 2024: $652 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $534.48 | 2024-2025 | Enhertu, Datroway |
| Novo Nordisk INC | $414.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $323.21 | 2019-2024 | Repatha, Otezla, Prolia |
| Harmony Biosciences LLC | $318.50 | 2020-2025 | Wakix |
| Amarin Pharma, INC. | $202.51 | 2019-2021 | |
| Abbvie INC. | $149.95 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $145.81 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $137.12 | 2019-2022 | |
| Livanova USA, INC. | $101.91 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Eli Lilly and Company | $101.20 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $100.61 | 2019-2025 | Farxiga, Breztri |
| Neurelis, INC. | $95.82 | 2024 | Valtoco |
| Bausch Health US, LLC | $67.17 | 2019 | |
| Abbott Laboratories | $62.29 | 2022-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $57.31 | 2023-2024 | Veozah, Myrbetriq |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.